Results 91 to 100 of about 5,026 (202)

Mettl3‐Mediated m6A Modification Represents a Novel Therapeutic Target for FSGS

Advanced Science, Volume 13, Issue 10, 18 February 2026.
This study explores the roles of Mettl3‐induced N6‐methyladenosine (m6A) modifications in Focal segmental glomerulosclerosis (FSGS). The findings reveal that inhibition of Mettl3 results in podocyte injury by modulating the TJP1CDC42 pathway. Moreover, Administration of N6‐methyladenosine attenuates the FSGS phenotype in WT mice induced by Adriamycin ...
Fubin Zhu, Hongzhi Li, Xiang Li, Chunxiu Du, Ting Wang, Xuling Zhou, Xiaobei Xie, Yunxia Shao, Yingzhi Huang, Yanling Hu, Xinxin Guo, Bin Zhu, Shanshan Yu, Xiaoyan Zhang, Binghai Zhao   +14 more
wiley   +1 more source

suPAR as a prognostic biomarker in critically ill patients

, 2013
suPAR as a prognostic biomarker in critically ill ...
Grazulyte D, Covajes C, GOTTIN, Leonardo, Scolletta S, Santonocito C, Obergozo Cortes D, DONADELLO, Katia, Taccone FS, Vincent J.L.   +8 more
core   +1 more source

Could soluble urokinase plasminogen receptor (suPAR) be used as a diagnostic biomarker for ventilator‐associated pneumonia?

, 2017
BackgroundSoluble urokinase plasminogen activator receptor (suPAR) is a biomarker that is increasingly used for evaluation of systemic inflammation. This study was performed to investigate whether suPAR may possess a diagnostic value in patients with ...
Adiyaman, Firat, Aysel Sunnetcioglu, Mahmut Sunnetcioglu, Sünnetçioğlu, Mahmut, Soyoral, Lokman, Sünnetçioğlu, Aysel, Lokman Soyoral, Fırat Adıyaman, Irfan Binici, Binici, Irfan   +9 more
core   +1 more source

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Demographic characteristics of the study patients by suPAR tertile.

, 2017
Demographic characteristics of the study patients by suPAR tertile.
Takahide Ito (495210), Yoshihiro Takeda (2413891), Shu-ichi Fujita (456246), Nobukazu Ishizaka (456250), Hideaki Morita (353346), Daichi Maeda (749664), Tomohiro Fujisaka (3704488), Suguru Tanaka (3155118)   +7 more
core   +1 more source

Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases

, 2023
The soluble urokinase plasminogen activator receptor (suPAR) is the bioactive form of uPAR, a membrane-bound glycoprotein, and it is primarily expressed on the surface of immunologically active cells.
Riccardo De Luca, Mariangela Manfredi, Pamela Bernardini, Maria Infantino, Edda Russo, Amedeo Amedei, Valentina Grossi, Serena Guiducci, Xavier Bossuyt, Carlo Perricone, Maurizio Benucci, Carmela Coccia, Lieve Van Hoovels   +12 more
core   +1 more source

The uPA/uPAR System and suPAR in HIV Infection

, 2010
The urokinase Plasminogen Activator Receptor (uPAR) is linked to the surface of immune cells and involved in multiple immune functions including cell adhesion, chemotaxis, migration, angiogenesis, fibrinolysis, proliferation, differentiation and signal ...
Haastrup, Eva, Langkilde, Anne, Ostrowski, Sisse R., Anne Langkilde, Sisse R. Ostrowski, Ullum, Henrik, Henrik Ullum, Eva Haastrup, Eugen-Olsen, Jesper, Jesper Eugen-Olsen   +9 more
core   +1 more source

SuPAR predicts postoperative complications and mortality in patients with asymptomatic aortic stenosis [PDF]

, 2018
Background We evaluated whether early measurement of soluble urokinase plasminogen activator receptor (suPAR) could predict future risk of postoperative complications in initially asymptomatic patients with mild-moderate aortic stenosis (AS) undergoing ...
Casper N Bang, Bang, Casper N., Antero Y Kesäniemi, Ray, Simon, Eugen-Olsen, Jesper, Jeppesen, Jørgen L., Boman, Kurt,, Michael H Olsen, Kristian Wachtell, Simon Ray, Hodges, Gethin W., Bang, Casper N, Kesäniemi, Antero Y., Boman, Kurt, Jørgen L Jeppesen, Jesper Eugen-Olsen, Kurt Boman, Olsen, Michael H, Gethin W Hodges, Olsen, Michael H., Hodges, Gethin W, Kesäniemi, Antero Y, Jeppesen, Jørgen L, Wachtell, Kristian   +23 more
core   +1 more source

PTSD and suPAR: A multicohort investigation of chronic inflammation

Brain, Behavior, and Immunity
Posttraumatic stress disorder (PTSD) is associated with poor health. Prior research has shown stressful events are associated with inflammatory biomarkers, such as soluble urokinase plasminogen activator receptor (suPAR), suggesting systemic chronic inflammation could be a mechanism linking adversity to poor health.
Kyle J. Bourassa, Terrie E. Moffitt, Louise Arseneault, Ashleigh Barrett-Young, Andrea Danese, Melanie E. Garrett, Renate Houts, Timothy Matthews, Richie G. Poulton, Sandhya Ramrakha, Stefan Sprinckmoller, Karen Sugden, Benjamin Williams, Jean C. Beckham, Allison E. Ashley-Koch, Nathan A. Kimbrel, Helen L. Fisher, Reremoana F. Theodore, Avshalom Caspi, Line J.H. Rasmussen   +19 more
openaire   +3 more sources

Host Response Biomarker in Sepsis: suPAR Detection

, 2014
Recent studies of our group have shown that suPAR may complement APACHE II score for risk assessment in sepsis. suPAR may be measured in serum of patients by an enzyme immunosorbent assay developed by Virogates (suPARnostic™). Production of suPAR from circulating neutrophils and monocytes may be assessed after isolation of neutrophils and monocytes and
Giamarellos-Bourboulis, Evangelos J., Georgitsi, Marianna   +1 more
openaire   +3 more sources